Objectives: This study was designed to investigate whether transmyocardial laser revascularization induces myocardial denervation and to correlate this with myocardial perfusion and clinical status.
Methods: Transmyocardial laser revascularization was performed with a Holmium:YAG (n = 3) or xenon chloride excimer laser (n = 5). Preoperative and postoperative iodine 123-labeled meta-iodobenzylguanide SPECT scintigraphy to assess cardiac innervation and perfusion scintigraphy were also performed. Furthermore, New York Heart Association functional angina class and quality of life were assessed.
Results: In all patients postoperative iodine 123-labeled meta-iodobenzylguanide SPECT showed significantly decreased uptake and therefore sympathetic myocardial denervation at up to 16 months' follow-up (average preoperative and postoperative summed defect scores of 14.8 +/- 5.3 and 24.5 +/- 4.2, respectively; P =.00005). In 86% of segments, the decreased meta-iodobenzylguanide uptake could be correlated to the treated area. In all patients angina was reduced by 2 or more classes at 12 months' follow-up, and quality of life improved significantly.
Conclusions: Transmyocardial laser revascularization-induced improvement of angina and quality of life can be explained by destruction of nociceptors or cardiac neural pathways, changing the perception of anginal pain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0022-5223(03)00973-5 | DOI Listing |
Cureus
May 2024
Department of Research, NFSci, LLC, Tucson, USA.
Background Coronary artery disease (CAD) is a global health burden, contributing to mortality and morbidity. A proportion of patients with CAD suffer from diffuse CAD, where conventional revascularization techniques such as percutaneous coronary intervention and coronary artery bypass grafting (CABG) may be insufficient to adequately restore myocardial perfusion. Transmyocardial revascularization (TMR) uses a laser to create microscopic channels in the myocardium, inducing inflammation, angiogenesis, and neovascularization to improve perfusion to ischemic regions.
View Article and Find Full Text PDFCurr Pharm Des
September 2023
1st Cardiology Department, "Hippokration" General Hospital, University of Athens Medical School, Athens, Greece.
Stem Cell Rev Rep
April 2023
Department of Cardiothoracic Surgery, University of Kentucky, Lexington, KY, USA.
Objective: We tested the hypothesis that targeted TMLR combined with intramyocardial injection of autologous CD 133 progenitor cells is safe and feasible in patients with chronic ischemic cardiomyopathy (ICM) and no revascularization options.
Methods: Eight male patients (age 62 ± 2.4 years) with multivessel severe ischemic heart disease and no revascularization options were enrolled.
J Lasers Med Sci
September 2021
Department of Cardiology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!